デフォルト表紙
市場調査レポート
商品コード
1427737

カルバペネム系抗生物質の世界市場レポート 2024

Carbapenem-Based Antibiotics Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
カルバペネム系抗生物質の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

カルバペネム系抗生物質の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には5.2%の年間複合成長率(CAGR)で57億1,000万米ドルに成長すると予想されます。予測期間中に予想される成長の原動力は、院内感染の発生率の増加、多剤耐性株の出現、高齢化人口の増加、外科手術の増加、感染症の急増、人口動態の変化などの要因です。予測期間中に予想される主な動向には、サプライチェーンの回復力と安全性の重視、代替治療法の開発、外来患者設定へのシフト、抗菌薬スチュワードシップに対する意識の高まり、精密医療アプローチの採用などがあります。

カルバペネム系抗生物質市場の成長予測の上昇は、細菌感染症の発生率の増加に起因すると考えられます。細菌として知られる微生物によって引き起こされるこれらの感染症は、さまざまな病気や症状を引き起こします。 カルバペネム系抗生物質は、グラム陽性菌とグラム陰性菌の両方を含む、重篤な細菌感染症または多剤耐性細菌感染症に対処するために特別に設計されています。たとえば、2022年 11月に英国保健安全庁(UKHSA)が報告したように、2021年に予測される抗生物質耐性の重症感染症の総数は2.2%増加しました。したがって、細菌感染症の急増がカルバペネム系抗生物質市場の成長を促進する主要なドライバーとなっています。

手術件数の増加により、カルバペネム系抗生物質市場の拡大が予想されます。外科的処置には、身体のさまざまな部分に影響を与える病気、怪我、状態に対処するために、資格のある外科医によって行われるさまざまな医療介入が含まれます。カルバペネムは幅広い活性を示し、腹腔内の感染症と効果的に闘い、併用療法の必要性を減らし、外科患者の治療プロトコルを簡素化し、髄膜炎の治療に有効であることが証明されています。たとえば、2022年 6月の米国代謝・肥満外科学会(ASMBS)のデータによると、2021年に約262,893件の肥満手術が行われたことが明らかになりました。したがって、外科手術の増加はカルバペネム系抗生物質市場の成長に直接寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年~2023年
  • 世界の市場規模予測と成長、2023年~2028年、2033年

第6章 市場セグメンテーション

  • 世界のカルバペネム系抗生物質市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • メロペネム
  • イミペネム
  • ドリペネム
  • テビペネム
  • その他のタイプ
  • 世界のカルバペネム系抗生物質市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 腹腔内感染症
  • 尿路感染症
  • 肺炎
  • 細菌性髄膜炎
  • 皮膚および皮膚構造の感染症
  • 急性骨盤感染症
  • 手術部位感染の予防
  • 気道感染症
  • 婦人科感染症
  • その他の適応症
  • 世界のカルバペネム系抗生物質市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 地域および国の分析

  • 世界のカルバペネム系抗生物質市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のカルバペネム系抗生物質市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • カルバペネム系抗生物質市場の競合情勢
  • カルバペネム系抗生物質市場の企業プロファイル
    • Pfizer Inc.
    • Merck &Co. Inc.
    • Saint-Gobain SA
    • Fresenius Kabi LLC
    • GlaxoSmithKline Plc

第31章 その他の大手および革新的な企業

  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca plc
  • Meiji Holdings Co. Ltd.
  • Sandoz International GmbH
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Shionogi &Co Ltd.
  • Aurobindo Pharma Ltd.
  • Acurx Pharmaceuticals, LLC
  • Daewoong Pharmaceutical Co. Ltd.
  • CeramTec GmbH
  • ACS Dobfar SpA
  • JW Pharmaceutical Corp
  • Centrient Pharmaceuticals Co
  • Spero Therapeutics Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13581

Carbapenem-based antibiotics represent a class of broad-spectrum antibacterial drugs known for their high efficacy against various bacterial infections. These antibiotics are particularly effective against both gram-positive and gram-negative bacteria, including strains that may be resistant to other types of antibiotics.

The primary types of carbapenem-based antibiotics include meropenem, imipenem, doripenem, tebipenem, and others. Meropenem, for instance, is a broad-spectrum antibiotic that works by inhibiting bacterial cell wall synthesis, making it effective against a wide range of bacterial infections. It is employed in the treatment of serious bacterial infections such as pneumonia, meningitis, intra-abdominal infections, urinary tract infections, and skin and soft tissue infections. Carbapenem-based antibiotics find application in treating various conditions, including intra-abdominal infections, urinary tract infections, pneumonia, bacterial meningitis, skin and skin structure infections, acute pelvic infections, prophylaxis of surgical site infection, respiratory tract infections, and gynecologic infections. These antibiotics are available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The carbapenem-based antibiotics market research report is one of a series of new reports from The Business Research Company that provides carbapenem-based antibiotics market statistics, including the carbapenem-based antibiotics industry's global market size, regional shares, competitors with a carbapenem-based antibiotics market share, detailed carbapenem-based antibiotics market segments, market trends, and opportunities, and any further data you may need to thrive in the carbapenem-based antibiotics industry. This carbapenem-based antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The carbapenem-based antibiotics market size has grown strongly in recent years. It will grow from $4.43 billion in 2023 to $4.66 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth observed in the historic period can be attributed to factors such as the occurrence of epidemics and pandemics, an increase in chronic diseases, expansion of healthcare infrastructure, rapid urbanization, and the impact of natural disasters and health emergencies.

The carbapenem-based antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.71 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The anticipated growth in the forecast period is driven by factors such as the increased incidence of hospital-acquired infections, the emergence of multi-drug resistant strains, a growing aging population, a rise in surgical procedures, the proliferation of infectious diseases, and changing demographics. Major trends expected in the forecast period include a focus on supply chain resilience and security, the development of alternative treatment options, a shift towards outpatient settings, a growing awareness of antimicrobial stewardship, and the adoption of precision medicine approaches.

The projected rise in carbapenem-based antibiotics market growth is attributed to the escalating incidence of bacterial infections. These infections, caused by microscopic organisms known as bacteria, lead to various diseases and symptoms. Carbapenem-based antibiotics are specifically designed to address severe or multidrug-resistant bacterial infections, encompassing both gram-positive and gram-negative bacteria. For instance, as reported by the UK Health Security Agency (UKHSA) in November 2022, there was a 2.2% increase in anticipated total antibiotic-resistant severe infections in 2021. Hence, the surge in bacterial infections is a key driver propelling the growth of the carbapenem-based antibiotics market.

The expansion of the carbapenem-based antibiotics market is anticipated due to the rising number of surgical procedures performed. Surgical procedures encompass a range of medical interventions carried out by qualified surgeons to address diseases, injuries, or conditions affecting different body parts. Carbapenems exhibit a wide spectrum of activity, effectively combating infections within the abdominal cavity, reducing the necessity for combination therapy, simplifying treatment protocols for surgical patients, and proving efficacious in meningitis treatment. For instance, data from the American Society for Metabolic and Bariatric Surgery (ASMBS) in June 2022 revealed that approximately 262,893 bariatric surgeries were conducted in 2021. Therefore, the escalation in surgical procedures directly contributes to the growth of the carbapenem-based antibiotics market.

The prevailing trend driving the carbapenem-based antibiotics market is the emphasis on product innovations. Major industry players within this market segment are actively engaged in innovating their product lines as a strategic approach to maintain their market positions. For example, in September 2021, BDR Pharmaceuticals International Pvt. Ltd., an India-based pharmaceutical company, introduced biapenem into the market. Biapenem is specifically designed for individuals afflicted with lower respiratory infections, complex urinary tract infections, or intra-abdominal infections. Clinical studies have showcased that Biapenem exhibits both clinical and bacteriological efficacy comparable to imipenem/cilastatin in treating patients affected by these ailments.

Leading companies operating in the carbapenem-based antibiotics market are directing their focus towards investments to augment their market revenues. A case in point is Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, which, in June 2021, allocated $40 million in investment toward Spero Therapeutics Inc. This investment granted Pfizer the rights to develop, produce, and market SPR206 outside of the United States and Asia. This financial arrangement is expected to bolster the ongoing clinical advancement of SPR720 and SPR206, providing Spero with substantial financial flexibility and capital. Pfizer's investment aligns with its strategic objective of fostering pioneering research and meeting patient needs, while concurrently empowering Spero to advance clinical development and expand global access to their products. Spero Therapeutics Inc., a US-based biopharmaceutical company dedicated to creating novel therapies for bacterial infections, stands to benefit significantly from this collaboration.

In September 2022, GSK PLC, a pharmaceutical and biotechnology company based in the UK, and Spero Therapeutics, Inc. entered into an exclusive license agreement. The agreement involved an upfront payment of $66 million, with the potential for future milestone payments and tiered royalties. This exclusive license granted GSK the commercialization rights for tebipenem HBr in all regions except for Japan and certain other Asian countries. Spero Therapeutics, a US-based clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments and medicines for bacterial infections, including multi-drug resistant and rare diseases, particularly in the realm of carbapenem oral antibiotics.

Major companies operating in the carbapenem-based antibiotics market report are Pfizer Inc., Merck & Co. Inc., Saint-Gobain S.A., Fresenius Kabi LLC, GlaxoSmithKline PLC, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AstraZeneca PLC, Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Acurx Pharmaceuticals LLC, Daewoong Pharmaceutical Co. Ltd., CeramTec GmbH, ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Amedica Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics PLC, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation

North America was the largest region in the Carbapenem-Based Antibiotics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the carbapenem-based antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The carbapenem-based antibiotics market consists of sales of imipenem-cilastatin, meropenem, ertapenem, doripenem, biapenem, panipenem, tebipenem, razupenem, tomopenem, and faropenem. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Carbapenem-Based Antibiotics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on carbapenem-based antibiotics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for carbapenem-based antibiotics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The carbapenem-based antibiotics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Meropenem; Imipenem; Doripenem; Tebipenem; Other Types
  • 2) By Indication: Intra-abdominal Infections; Urinary Tract Infections; Pneumonia; Bacterial Meningitis; Skin and Skin Structure Infections; Acute Pelvic Infections; Prophylaxis of Surgical Site Infection; Respiratory Tract Infections; Gynecological Infections; Other Indications
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Saint-Gobain S.A.; Fresenius Kabi LLC; GlaxoSmithKline Plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Carbapenem-Based Antibiotics Market Characteristics

3. Carbapenem-Based Antibiotics Market Trends And Strategies

4. Carbapenem-Based Antibiotics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Carbapenem-Based Antibiotics Market Size and Growth

  • 5.1. Global Carbapenem-Based Antibiotics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Carbapenem-Based Antibiotics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Carbapenem-Based Antibiotics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Carbapenem-Based Antibiotics Market Segmentation

  • 6.1. Global Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Meropenem
  • Imipenem
  • Doripenem
  • Tebipenem
  • Other Types
  • 6.2. Global Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Intra-abdominal Infections
  • Urinary Tract Infections
  • Pneumonia
  • Bacterial Meningitis
  • Skin and Skin Structure Infections
  • Acute Pelvic Infections
  • Prophylaxis of Surgical Site Infection
  • Respiratory Tract Infections
  • Gynecological Infections
  • Other Indications
  • 6.3. Global Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Carbapenem-Based Antibiotics Market Regional And Country Analysis

  • 7.1. Global Carbapenem-Based Antibiotics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Carbapenem-Based Antibiotics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Carbapenem-Based Antibiotics Market

  • 8.1. Asia-Pacific Carbapenem-Based Antibiotics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Carbapenem-Based Antibiotics Market

  • 9.1. China Carbapenem-Based Antibiotics Market Overview
  • 9.2. China Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Carbapenem-Based Antibiotics Market

  • 10.1. India Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Carbapenem-Based Antibiotics Market

  • 11.1. Japan Carbapenem-Based Antibiotics Market Overview
  • 11.2. Japan Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Carbapenem-Based Antibiotics Market

  • 12.1. Australia Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Carbapenem-Based Antibiotics Market

  • 13.1. Indonesia Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Carbapenem-Based Antibiotics Market

  • 14.1. South Korea Carbapenem-Based Antibiotics Market Overview
  • 14.2. South Korea Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Carbapenem-Based Antibiotics Market

  • 15.1. Western Europe Carbapenem-Based Antibiotics Market Overview
  • 15.2. Western Europe Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Carbapenem-Based Antibiotics Market

  • 16.1. UK Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Carbapenem-Based Antibiotics Market

  • 17.1. Germany Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Carbapenem-Based Antibiotics Market

  • 18.1. France Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Carbapenem-Based Antibiotics Market

  • 19.1. Italy Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Carbapenem-Based Antibiotics Market

  • 20.1. Spain Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Carbapenem-Based Antibiotics Market

  • 21.1. Eastern Europe Carbapenem-Based Antibiotics Market Overview
  • 21.2. Eastern Europe Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Carbapenem-Based Antibiotics Market

  • 22.1. Russia Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Carbapenem-Based Antibiotics Market

  • 23.1. North America Carbapenem-Based Antibiotics Market Overview
  • 23.2. North America Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Carbapenem-Based Antibiotics Market

  • 24.1. USA Carbapenem-Based Antibiotics Market Overview
  • 24.2. USA Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Carbapenem-Based Antibiotics Market

  • 25.1. Canada Carbapenem-Based Antibiotics Market Overview
  • 25.2. Canada Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Carbapenem-Based Antibiotics Market

  • 26.1. South America Carbapenem-Based Antibiotics Market Overview
  • 26.2. South America Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Carbapenem-Based Antibiotics Market

  • 27.1. Brazil Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Carbapenem-Based Antibiotics Market

  • 28.1. Middle East Carbapenem-Based Antibiotics Market Overview
  • 28.2. Middle East Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Carbapenem-Based Antibiotics Market

  • 29.1. Africa Carbapenem-Based Antibiotics Market Overview
  • 29.2. Africa Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Carbapenem-Based Antibiotics Market Competitive Landscape And Company Profiles

  • 30.1. Carbapenem-Based Antibiotics Market Competitive Landscape
  • 30.2. Carbapenem-Based Antibiotics Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck & Co. Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Saint-Gobain S.A.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Fresenius Kabi LLC
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. GlaxoSmithKline Plc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Carbapenem-Based Antibiotics Market Other Major And Innovative Companies

  • 31.1. Eli Lilly and Company
  • 31.2. Teva Pharmaceutical Industries Ltd.
  • 31.3. AstraZeneca plc
  • 31.4. Meiji Holdings Co. Ltd.
  • 31.5. Sandoz International GmbH
  • 31.6. Sumitomo Dainippon Pharma Co. Ltd.
  • 31.7. Shionogi & Co Ltd.
  • 31.8. Aurobindo Pharma Ltd.
  • 31.9. Acurx Pharmaceuticals, LLC
  • 31.10. Daewoong Pharmaceutical Co. Ltd.
  • 31.11. CeramTec GmbH
  • 31.12. ACS Dobfar S.p.A
  • 31.13. JW Pharmaceutical Corp
  • 31.14. Centrient Pharmaceuticals Co
  • 31.15. Spero Therapeutics Inc.

32. Global Carbapenem-Based Antibiotics Market Competitive Benchmarking

33. Global Carbapenem-Based Antibiotics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Carbapenem-Based Antibiotics Market

35. Carbapenem-Based Antibiotics Market Future Outlook and Potential Analysis

  • 35.1 Carbapenem-Based Antibiotics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Carbapenem-Based Antibiotics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Carbapenem-Based Antibiotics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer